Neuropilins - Past, Present and Future: A Review of Its Anti-Neoplastic Potential
International Journal of Anesthesia and Clinical Medicine
Volume 6, Issue 1, June 2018, Pages: 10-14
Received: Feb. 10, 2018; Accepted: Feb. 25, 2018; Published: Apr. 3, 2018
Views 1501      Downloads 82
Ekpe E. L., Department of Chemical Pathology/Immunology, University of Calabar Teaching Hospital, Calabar, Nigeria
Okorie Elsie, Department of Chemical Pathology/Immunology, University of Calabar Teaching Hospital, Calabar, Nigeria
Emin Emin, Department of Chemical Pathology/Immunology, University of Calabar Teaching Hospital, Calabar, Nigeria
Ekpe Victor, Dornsife School of Public Health, Drexel University, Philadelphia, USA
Article Tools
Follow on us
Recently, cancer progression has been linked to a trans-membrane receptor, neuropilin. Studies show that neuropilins are widely distributed in the body and these receptors appear to control the vasculirization of tumors. Neuropilins 1 and 2 are known to be involved in angiogenesis and vascular development and are receptors for vascular endothelial growth factor (VEGF) and the class 3 semaphorins. Angiogenesis, which is a feature of many malignancies, is aided by increased neuropilin expression. Hence, high neuropilin expression correlates with tumor progression and poor prognosis. Attempts are being made to suppress tumor growth and invasion by employing agents that suppress angiogenesis. This is of great interest, because blockade or inhibition of these molecules may be used as therapeutic agents in cancer therapy. In this review, the molecular biology and current knowledge of neuropilins are explored with a view to identifying their therapeutic potentials. In conclusion, neuropilin targeted intervention may be relevant as anti-cancer therapy.
Neuropilin, Semaphorins, Angiogenesis, VEGF, Malignancy, Receptor, Therapy
To cite this article
Ekpe E. L., Okorie Elsie, Emin Emin, Ekpe Victor, Neuropilins - Past, Present and Future: A Review of Its Anti-Neoplastic Potential, International Journal of Anesthesia and Clinical Medicine. Vol. 6, No. 1, 2018, pp. 10-14. doi: 10.11648/j.ja.20180601.13
Copyright © 2018 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License ( which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Ellis LM. The Role of Neuropilins in Cancer. Molecular Cancer 2006; 5 (5): 1099-1107.
Chaudhary B., Khaled YS, Ammon BJ. Neuropilin 1: Function and Therapeutic Potentials in Cancer. Cancer Immuno Immunother 2014; 63 (2):81-99.
Pellet-Mary C., Frankel P., Haiyen J., Zachary I. Neuropilins: Structure, Function and Role in Disease. Biochemical Journal, 2008; 41 (2): 211-226.
Sokers S, Takashima S, Micro HQ, Neufeld G, Klagsbrun M. Neuropilin 1 is expressed by endothelial and tumor cells as an iso-form-specific receptor for vascular endothelial factor. Cell. 1998; 92 (6): 375-743.
Neufeld G, Kessler O, Herzog Y. The interaction of neuoropilin1 and 2 with tyrosine. Adv Exp Med 2002, 515; 81-90.
Neuropilin. In: https.:
Jarris A., Allerston C. K. Jia H., Herzog B., Garza-Garca A., Winfeld N., small nucleus inhibitors of the Neuropilins 1 vascular endothelial growth factor A (VEGFA). Internation J Med Chem. 2010; 53 (5):215-226.
Mercollan V., Nieuwenhuis J., Verhaagen. A perspective on the role of class III semaphorins signaling in central nervous system trauma. Frontiers in Cellular Neuro Science 2014; 8:328.
Hendricks C., Dubai J., Brohee L., Delforge T., Colige A. A novel physiological gycosaminoglycans deficient splice variant of neuropilins 1 in anti-tumorigenic in invitro and invivo. PL0S ONE 2016; 11 (10): eo165153.
Chen H, Bagri A, Zupicich JA, Zou Y, Stoeckli E. neuropilin 2 regulates the development of selected cranial and semsory nerves and hippocampus mossy fiber projections. Neuron. 2000; 25 (1):43-56.
Kofler NM., Simons M., Angiogenesis versus arteriogenesis: Neuropilins 1 modulation of VEGF signaling. F1000 Prime Rep 2015, 7:16.
Valembri D., Caswell PI., Anderson KJ., Schwartz JP. Neuropilin 1/GIPC 1 signaling regulates α5β, integin traffic and function in endothelial cells. PL0S Biol 2009; 7 (1): e1000025.
Herzog Y., Kalcheim C., Kahane N., Neufeld G. Differential expression of Neuropilin 1 and 2 in arteries and veins. Mechanisms of Action. 2001; 109 (1) 115-1191.
Koch S. Neuropilin signaling in angiogenesis. Biochemical society transactions 2012; 40 (Part 1).
Guo H. F., Vander-Kooi C. W. – Neuropilin function as an essential cell surface receptor. Journal of Biological Chemistry. 2015; doi 10:1074/JBC.
Aci-Seche S., Sawma P., Hubert P., Sturgis J. N., Baghard D. Transmembrane recognition of the semaphoring receptor neuropilin and plexin A1. PL0S ONE. 2014; 9 (5). C97779.
Parker MW, Guo HF, Xiaobo Li, Linkugel AD., VanderKooil CW. Function of the neuropilin family an essential pleiotropic cell surface receptor. Biochemistry. 2012; 51 (47): 9437-9446.
Fuh G., Garcia K. C. de vos AM. The interaction of neuropilin 1 and VEGF and it receptor flt-1. Journal of Biological Chemistry 2000; 6: doi 10. 1074 IJb.
Yelland T., Djordjeric S., Crystal structure of the Neuropilin 1. MAM Domain completing the Neuropilin 1 ectodomain picture. 2016; 2491): 2008-2015.
Nakamura F., Goshima Y. Structure and Functional Relation of Neuropilins. In: Madam Curie Bioscience data. Bioscience 2000-2013.
Fujisawa H. Discovery of semaphorin receptors, Neuropilin and plexins, and their function in neural development. J Neurobiol 2004; 59 (1): 24-33.
Klagsbrun M., Takashima S., Mamluk R. In: The role of neuropilins in vascular and tumor Biology (Neuropilins: from Nervous systems to vascular and tumor Biology): 515:33-48.
Takagi S., Kasuya Y, Shimiza M., Matsuura T., Tsuboi M., Kawakami A., Fujisawa H. Expression of a cell adhesion molecule, neuropilin in the developing chick nervous system. Dev Biol 1995: 170 (1). 207-22.
Chen C., Li M., Yang H., Fisher W. E., Yau Q. Roles of neuropilins in neuronal development angiogenesis and cancers. World J Surg 2005; 29 (3): 271-5.
Kumanogoh AH. immunological functions of the neuropilins and plexins as receptors for semaphorins. Immunology. 2013; 13 (11):802-14.
Kolodkin AL., Levengood DV., Rowe EG., Tai TT., Giger RJ., Ginty DD. Neuropilin is a semaphoring III receptor. CELL 1997, 90 (4): 753-762.
Chen H., Chedotal A., He Z, Goodman CS. Lavigne MT. Neuropilin-2 is a novel member of the neuropilins family, is a high affinity receptor for the semaphorins SEMA E and SEMA IV but not SEM III. 1997; 19 (3) 547-59.
Nasarre P., GemMill RM., Drabkion HA. The emerging role of class 3 semaphorins and the neuropilins receptors in oncology. Onco Targets Ther. 2014;(7): 1663-1687.
Sharma A., Verhaagen J., Harvey A. R. Receptor complexes for each of the class 3 semaphorins. Frontiers in cellular neurosciences 6:28 doi 10.3389.
Winter F. D., Holtmaat A. J., Verhaagen J., Neuropilins and class 3 semaphorins in nervous system regeneration. In: Madam Curie Bioscience database. 2013.
Gelfan MV., Itagan N., Tata A., Oh WJ., Lacoste B. Neuropilin 1 function as a VEGFR 2 co-receptors to guide developmental angiogenesis independent of ligand binding. eLife. 2014; 3. Eo3720.
Gabham FM., Popel AS. Targeting Neuropilin 1 to inhibit VEGF Signaling in cancer. Comparism of the therapeutic approaches. PLOS Comput Biol 2006; 2 (12): e180.
Danen EH. Intergrins signaling as cancer drug target – Cell Biology 2013 (2013). ARTICLE ID. 135164.
Lim J., Christine P. Neuropilins-1 expressed by endothelial cells and retinal pigment epithelial cells in choroidal vascular membrane. Am J. of Ophthalmology. 2005. 140: (6): 1044-1050.
Maden C. H., Fantin A., Ruhrberg C. Neuropilins Ligand in vascular and neaosnal patterning. Biochemical society transaction. 2009: 37 (6).
Wild JR., Station CA., Corfe RM. Int. J. Exp Pathol 2012; 93 (2): 81-103.
Takashima S., Kitakaze M., Asakura M., Assaauma I. E. Targeting of both mause neuropilin 1 and neuropilin 2 geres severely in pains developmental yoyk sac and embryonioc angiogenesis PNAS 2002 99 (6) 3657-3662.
Karja Laimen K., Jaulouk DE., Bueso-Ramos C. E., Zurita A. J., Kuniyasu A., Eckhardt B. L. Targeting neuropilin 1 in human leukemia and lymphoma Blood. 2011, 117 (3): 920-927.
Tse BW., Volpert M., Ratther E., Stylianou N., Noun M., McGown K. Neuropilin 1 in upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is a poor prognostic of metastatic progression and patient mortality. Oncogene 2017.
Parikh AA., Fan F., Liu W. B., Ahmed S. A., Neuropilin in human colon cancer: expression, regeneration aid role in induction of angiogenesis. Am J. Pathol. 2004: 164 (6). 2139-51.
Barr. MP., Gray SG., Gutely K., Hams E., Fallon PG. Vascular endothelial growth factor is an autocrine growth factor, signaling the NP1 in small cell lung cancer. Molecules Cancer 2015, 14: 45.
Yasuoka H., Kodama R., Tsujimot, Yoshidone K., Akamatsu H. Neuropilin 2 expression in breast cancer: correlation with lymph node metastatic, poor prognosis, and regulation of CXCR4 expression. BMC CANCER 2009; 9: 220.
Ding H. Expression and regulation of Neuropilin 1 in human astrocytoma. Cancer Cell Biology 2000. 88 (4). 554-592. 2.
Keck B., Wach S., Taubert H., Zeiler S. Neuropilin 2 and its ligand VEGF predict treatment response after transurethral resection and radio chemotherapy in bladder cancer patients. Int Journal Cancer. 2015, 136 (2): 443-457.
Shebani KO, Souba WW., Ott MJ. Prognosis and survival in patients with gastro-intestinal tract carcinoid tumors. Ann Surg 1999; 229 (6): 815.
Caunt M., Mak J., Liang WC, Stawicki S., Pan Q. Blocking neuropilin 2 function inhibits tumor cell metastasis. CANCER CELL 2008, 13 (4). 331-42.
Sharubi – Farahari S. Gallutini M., Martins F., Madge Nakayama H. Neuropilin 1 receptor is upregulated in dysplastic epithelium and oral squamous cell carcinoma. Am J. Pathol 2016, 186 (4): 1055-64.
Fukahi, Fukasawa M., Itakam J., Karc M., Aberrant expression of neuropilins 1 and 2 in human pancreatic cells. Clin Cancer Res. 2004, 10 (2): 581-90.
Gruziani G., Lacal P. M. Neuropilin 1 as a therapeutic target for malignant melanoma. Frontiers in Oncology. 2015: 5 (125). 0.
Kigel B., Varsharsky, Kessler O., Neufeld G. Successful inhibition of Tumor development by class 3 Sema is associated with expression of appropriate semaphoring Receptors by cells. PLOS ONE 2008; 3 (9): e3287.
Kusama T, Mukai M, Tatsuta M, Nakamura H, Inoue M. inhibition of transendothelial migration and invasion of human cells by preventing geranylgeranyllation of Rho. Int Journal of Oncology 2006; 29 (1):217-223.
Folkman J. Tumor angiogenesis: Therapeutic implications. NEJM 1971; 285: 1182-1186.
Djordjevic S., Driscoll P. C. Targeting VEGF signaling via the neuropilin receptor. Drug Discovery Today 2013; 18 (9): 447-455.
Gagman ML., Bidenberg DR., Gechtman Z., Miao HQ., Takashima S. Identification of a national soluble neuropilin 1 that backs vascular endothelial growth factor: In-vivo expression all antitumor activity1. Proceedings of the National Academy of Science of the United States by America 97 (6): 2573-8.
Henry TD., Annex B. H., McKendall GR., Azrin MA., Lopez JJ. The VIVA trial. VEGF in ischaemia for vascular angiogenesis. Circulation 2003, 107:1359-1365.
Sato K., Laham R. J., Pearlman JD. Efficacy of Intra-coronary versus Intravenous FGF -2 in a pig model of chronic myocardial ischaemia. Ann Thorac Surg 2000; 70:2113-2118.
Osaadon P., Fagan XJ., Lifshitz T., Levy J. A review of anti-VEGF agents for proliferative diabetic retinopathy EYE. 2014 28 (5): 510-520.
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
Tel: (001)347-983-5186